Live

Watch: Fed Chair Jerome Powell speaks on interest rates, tariffs

OTC Markets EXMKT - Delayed Quote USD

AB Science S.A. (ABSCF)

1.5700

0.0000

(0.00%)

As of April 3 at 4:00:00 PM EDT. Market Open.

No Tool

Measure

UNDO

Redo

All

All

Favorites

Text

Statistics

Technicals

Fibonacci

Markings

Lines

Annotation

Arrow

Line

Horizontal

Vertical

Rectangle

Trend Line

Measurement Line

Average Line

Callout

Channel

Check

Continuous

Crossline

Elliott Wave

Ellipse

Doodle

Fib Projection

Fib Arc

Fib Fan

Fib Time Zone

Focus

Gann Fan

Gartley

Heart

Pitchfork

Quadrant Lines

Ray

Regression Line

Fib Retracement

Star

Speed Resistance Arc

Speed Resistance Line

Time Cycle

Tirone Levels

Volume Profile

Cross

Loading Chart for ABSCF

AB Science: Article from the leading publication Life Sciences Magazine featuring masitinib and its Phase 3 principal investigator, the neurologist Patrick Vermersch

AB Science: Article from the leading publication Life Sciences Magazine featuring masitinib and its Phase 3 principal investigator, the neurologist Patrick Vermersch

AB Science today provides an update on its masitinib platform

AB Science today provides an update on its masitinib platform

AB Science will host a live webcast on Tuesday January 28, 2025, from 5.30pm to 6.45pm CET

AB Science will host a live webcast on Tuesday January 28, 2025, from 5.30pm to 6.45pm CET

AB Science will participate in the Biomed Forum investors conference

AB Science will participate in the Biomed Forum investors conference

AB Science provides a summary of the webcast held on December 16, 2024

AB Science provides a summary of the webcast held on December 16, 2024

AB Science will host a live webcast on Monday December 16, 2024, from 5.30pm to 6.30pm CET

AB Science will host a live webcast on Monday December 16, 2024, from 5.30pm to 6.30pm CET

AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell disease

AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell disease

AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS

AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS

AB Science: Revenues for the first half of 2024 and update on AB Science’s activities

AB Science: Revenues for the first half of 2024 and update on AB Science’s activities

AB Science announces a slight delay in the publication of its 2024 half-year financial report

AB Science announces a slight delay in the publication of its 2024 half-year financial report

AB Science provides an update on the microtubule program AB8939 and in particular the ability of AB8939 to generate response on MECOM rearrangement

AB Science provides an update on the microtubule program AB8939 and in particular the ability of AB8939 to generate response on MECOM rearrangement